MERIDIAN, Idaho,
FineTech Pharmaceutical has an integrated team of 25 highly skilled and
educated scientists led by
"With the new acquisition of FineTech, our strategy to produce difficult
product formulas has been extensively expanded to include complex APIs,"
commented Earl E. Sullivan, the COO of RxElite. "
"FineTech holds the patents on difficult to produce APIs, therefore
generating significant non-US licensing opportunities, including annual
royalty opportunities," said RxElite's SVP Business Development,
The worldwide market for the finished dosage pharmaceuticals represented
by FineTech's APIs is in excess of
About RxElite, Inc.
RxElite, Inc. develops, manufactures and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics and injectable drugs) and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
For More Information: Corporate Information Ph: (208) 288-5550 Toll Free: (800) 414-1901 Fax: (208) 288-1191 Investor Relations Craig Bird, 215-885-4981 chbird@segue.biz Segue Ventures LLC
SOURCE RxElite, Inc.